Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 503 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-fasting Clear all

Conditions: Obesity, Diabetes
Interventions: slowly digestible carbohydrate; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Diabetes Mellitus, Type 1
Interventions: Fast-acting insulin aspart, iLet™; Drug · Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatic Insufficiency
Interventions: Mavorixafor; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Montclair, California • Rialto, California • Orlando, Florida + 1 more

Conditions: Mental Disorders
Interventions: Testing (MRS, US, DEXA, blood tests); Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 18 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin Glargine (HOE901 - U300), Insulin Glargine (HOE901 - U100), Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 65 Years and older
Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 64
States / cities: Saraland, Alabama • Fresno, California • Greenbrae, California + 57 more

Conditions: Healthy, Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 395 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2028
U.S. locations: 1
States / cities: Davis, California

Conditions: Healthy
Interventions: ARAVA® 20 mg tablets, Leflunomide 20 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 2
States / cities: Saint Charles, Missouri • Houston, Texas

Conditions: Cushing's Disease, Acromegaly
Interventions: Pasireotide s.c., Sitagliptin, Liraglutide, Insulin, Pasireotide LAR, Metformin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 15
States / cities: Multiple Locations, California • Torrance, California • Ventura, California + 10 more

Conditions: Preterm Infant
Interventions: Early/Slow, Early/Fast, Late/Slow, Late/Fast; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 32 Weeks
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: Gabapentin tablets 800 mg; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy Adults
Interventions: Crucera-SGS, Meriva 500-SF; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2605541, Insulin glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 33
States / cities: Mesa, Arizona • Phoenix, Arizona • Concord, California + 30 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: Bevacizumab and Erlotinib; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Stroke, Hemiparesis, Walking, Difficulty
Interventions: Augmented Feedback without Virtual Reality(VR, Augmented Feedback with Non-Game based VR, Augmented Feedback with Game based VR; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Not listed
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Birmingham, Alabama

Conditions: Diabetes Mellitus Type 2
Interventions: GK Activator (2); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 10
States / cities: Chandler, Arizona • Oviedo, Florida • Nampa, Idaho + 7 more

Conditions: Pharmacokinetics, Drug Interactions
Interventions: Dasatinib ASD, Omeprazole 40 MG; Drug
Lead sponsor: Xspray Pharma AB; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Smoking
Interventions: Informing surgical patients about CO monitoring, a brief intervention recommending preoperative abstinence from smoking; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Suicide, Attempted
Interventions: Ketamine Hydrochloride, Saline, CAMS Therapy; Drug · Behavioral
Lead sponsor: Tatiana Falcone, MD; Other
Eligibility: 14 Years to 30 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Inflammatory Bowel Disease, Crohn Disease
Interventions: Coronal T1 weighted spin echo images, Spin-lattice relaxation (T1), Magnetic resonance spectroscopy, Blood Draw; Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 13 Years to 20 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumor, Adult
Interventions: ASTX029; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 19
States / cities: Duarte, California • Los Angeles, California • Newport Beach, California + 13 more

Conditions: Healthy
Interventions: 5 mg/500 mg METAGLIP™ Tablets, 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 2
States / cities: East Grand Forks, Minnesota • Fargo, North Dakota

Conditions: Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Interventions: Metformin XR plus placebo, Metformin XR plus liraglutide; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Shigellosis
Interventions: 240 µg Shigella flexneri 2a Invaplex 50 vaccine, 480 µg Shigella flexneri 2a Invaplex 50 vaccine, 690 Shigella flexneri 2a Invaplex 50 vaccine, Shigella challenge strain; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Baltimore, Maryland • Silver Spring, Maryland

Conditions: Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions: Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin; Drug · Other · Dietary Supplement + 1 more
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Crossover Trials Which Assessed Consumption of Slowly Digestible Carbohydrates for 21 Days on Gastric Emptying Rates

Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Measurement of Cardiometabolic Risk in Antipsychotic-Treated Children

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Elucidation of Breast Milk Composition and Structure Over the First Year of Lactation: UC Davis Lactation Study

Leflunomide 20 mg Tablets, Non-Fasting

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

Testing Four Feeding Approaches to Oral Feeding in Preterm Infants

Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed Conditions

Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin

A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Effects of Different Types of Augmented Feedback on Intrinsic Motivation and Spatiotemporal Gait Performance After Stroke

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

Monitoring of Exhaled Carbon Monoxide to Promote Pre-operative Smoking Cessation

Ketamine Treatment of Youth Suicide Attempters

Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

Study of ASTX029 in Subjects With Advanced Solid Tumors

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection

Dexamethasone/Pancreatic Clamp P&F